Rockwell Medical, Inc. Confirms Medical Resource Acquisition Group’s Director Nominations Are Invalid
March 20 2020 - 8:30AM
Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the
“Company”), a biopharmaceutical company dedicated to transforming
anemia management and improving outcomes for patients around the
world, today reiterated that Medical Resource Acquisition Group LLC
(MRAG) failed to properly deliver a notice of director nominations
under the Company’s Bylaws within the prescribed advance notice
period.
While MRAG has continued its attempts to confuse shareholders
into believing otherwise, the Company has been abundantly clear in
its communications with MRAG and its advisors that MRAG’s three
director nominees will not stand for election at the Company’s 2020
annual meeting of stockholders. The Company will also make copies
of such correspondence available on our website,
https://ir.rockwellmed.com/. The Company continues to advise
shareholders to exercise caution in connection with this
matter.
Gibson, Dunn & Crutcher LLP is acting as legal counsel to
Rockwell Medical.
About Rockwell Medical
Rockwell Medical is a biopharmaceutical company dedicated to
transforming anemia management in a wide variety of therapeutic
areas and across the globe, improving the lives of very sick
patients. The Company’s initial focus is the treatment of anemia in
end-stage renal disease (ESRD). Rockwell Medical's exclusive renal
drug therapy, Triferic (ferric pyrophosphate citrate), is the only
FDA-approved therapeutic indicated for iron replacement and
maintenance of hemoglobin in hemodialysis patients. The Company has
developed multiple formulations of Triferic (1) FDA-approved
Dialysate Triferic, and (2) I.V. Triferic, for which the Company
filed a New Drug Application in May 2019. Rockwell Medical is also
an established manufacturer, supplier and leader in delivering
high-quality hemodialysis concentrates/dialysates to dialysis
providers and distributors in the U.S. and abroad.
Triferic® is a registered trademark of Rockwell Medical,
Inc.
Forward-Looking Statements
This press release may contain statements which may be
considered forward-looking within the meaning of the U.S. federal
securities laws. These statements are subject to known and unknown
risks, uncertainties and other factors that may cause our actual
results, performance or achievements to differ materially from
results expressed or implied in this press release. Additional
information is contained in the Risk Factors sections of Rockwell’s
most recent reports filed with the SEC on Form 10-K and Form 10-Q.
Rockwell does not intend to update these forward-looking statements
as a result of future events or developments.
ContactInvestor Relations: Lisa M. Wilson,
In-Site Communications, Inc. T: 212-452-2793 E:
lwilson@insitecony.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024